Spinelli M, Bertapelle P, Cappellano F, Zanollo A, Carone R, Catanzaro F, Giardiello G, De Seta F
Osp. Fornaroli, Magenta, CTO/CRF/MA, Torino, Policlinico Multimedica, Sesto S. Giovanni and Medtronic, Milano, Italy.
J Urol. 2001 Aug;166(2):541-5.
The Italian Register was created in February 1997 to collect the national results of sacral neuromodulation. All Italian centers at which sacral neuromodulation is performed were invited to participate in our study. We present the results from retrospective and prospective registers.
A total of 196 patients underwent permanent implantation of sacral neuromodulation and were enrolled in the Italian register. There were 18 males and 75 females in the retrospective, and 28 males and 75 females in the prospective studies. Student's t test was used to compare paired values, and the Wilcoxon rank sum and nonparametric tests were used when necessary.
Mean incontinent episodes daily plus or minus standard deviation for patients with detrusor instability went from 5.4 +/- 3.9 to 1.1 +/- 1.6 (median 5 and 0, respectively) at 12-month followup (p <0.001). For idiopathic retention average residual volume decreased from 277 to 108 cc (median 287 and 80, respectively), and 50% of patients stopped catheterization and another 13% catheterized once daily at 1-year after implantation. With neurogenic voiding disturbances, the results fluctuated with time from a minimum of 33% to a maximum 66% of patients who did not catheterize at 6-month followup and 12 months after implantation, respectively. At 12-month followup, 50% of patients with hyperreflexia had less than 1 incontinent episode daily. The problem was completely solved in 66% of patients in the retention group. Of patients in the urge incontinent population 39% were completely dry and 23% had less than 1 incontinent episode daily.
Sacral neuromodulation is effective therapy for treating lower urinary tract symptoms resistant to less invasive therapy.
意大利骶神经调节登记处创建于1997年2月,用于收集骶神经调节的全国性结果。所有进行骶神经调节的意大利中心均受邀参与我们的研究。我们展示了回顾性和前瞻性登记处的结果。
共有196例患者接受了骶神经调节永久性植入,并被纳入意大利登记处。回顾性研究中有18例男性和75例女性,前瞻性研究中有28例男性和75例女性。采用学生t检验比较配对值,必要时使用威尔科克森秩和检验及非参数检验。
逼尿肌不稳定患者每日尿失禁发作的平均次数加减标准差从5.4±3.9降至1.1±1.6(中位数分别为5和0),在12个月随访时(p<0.001)。特发性尿潴留患者的平均残余尿量从277毫升降至108毫升(中位数分别为287和80),50%的患者在植入后1年停止导尿,另有13%的患者每天导尿一次。对于神经源性排尿障碍,结果随时间波动,在植入后6个月和12个月随访时,分别有33%至66%的患者无需导尿。在12个月随访时,50%的反射亢进患者每日尿失禁发作少于1次。潴留组66%的患者问题得到完全解决。在急迫性尿失禁人群中,39%的患者完全无尿失禁,23%的患者每日尿失禁发作少于1次。
骶神经调节是治疗对侵入性较小的治疗有抵抗的下尿路症状的有效疗法。